• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Almirall Launches Wynzora Cream for Plaque Psoriasis in Europe


The calcipotriene and betamethasone dipropionate cream is for the treatment of mild to moderate plaque psoriasis in adult patients, including the scalp.

Almirall, a global biopharmaceuticalcompany, announced the European commercial launch of its 50 μg/g calcipotriol (CAL) and 0.5 mg/g betamethasone as dipropionate (BDP) (Wynzora) cream, developed for the topical treatment of mild to moderate plaque psoriasis in adultpatients,including scalp disease. The cream will be initially available for prescription in Spain, Germany, and the United Kingdom.

The CAL/BDP cream is created by PAD Technology, a method of mixing oil and water, which makes it the only calcipotriene and betamethasone dipropionate topical that allows the combination of active ingredients in an aqueous cream, according to the press release. The cream, according to Almirall, has a high efficacy and an onset within 1 week.

The results from a pooled analysis of 2 randomized phase 3 trials on the treatment demonstrated that the CAL/BDP PAD-cream had greater efficacy and patient quality of life in the topical treatment of psoriasis in comparison to the CAL/BDP gel formulation for all efficacy endpoints including physician’s global assessment (PGA) treatment success, modified Psoriasis Area and Severity Index (mPASI), and showed a PASI75 after 8 weeks of once-daily use.2

After 8 weeks of treatment, a significantly greater proportion of patients treated with CAL/BDP PAD-cream reported that psoriasis had no effect at all on their life, meaning adermatology life quality index (DLQI) of 0 or 1 compared to CAL/BDP gel.2 The patient’s main reason for accepting the CAL/BDP PAD-cream was due to the topical being a less greasy formulation, according to the researchers.

“In recent years we have observed vast improvements in the treatments available for psoriasis, however, adherence to topical treatments remains low. The arrival of a new PAD-cream formulation of CAL/BDP is excellent news for the psoriasis community, who now have a treatment option that combines efficacy and safety profile of the well-established CAL/BDP active ingredients in a newest vehicle technology for patient convenience.” said Anthony Bewley, BA Hons FRCP, consultant dermatologist, United Kingdom.


1. Almirall launches innovative Wynzora CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp. Yahoo News. Published February 18, 2022.Accessed February 18, 2022. https://www.yahoo.com/lifestyle/almirall-launches-innovative-wynzora-cal-095200172.html

2. Pinter A, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. JEADV. 2021; doi: 10.1111/JDV.17734.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.